General Information of Drug (ID: DM0GVZO)

Drug Name
ODN-1411 Drug Info
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Investigative [1]
Cross-matching ID
TTD Drug ID
DM0GVZO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Toll-like receptor 8 (TLR8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Resiquimod DML6XSP Actinic keratosis EK90.0 Phase 2 [2]
Selgantolimod DMST4OR Hepatitis B 1E51 Phase 2 [3]
Afimetoran DM3HN3U Systemic lupus erythematosus 4A40.0 Phase 2 [4]
NKTR-262 DMYR8LF Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
CPG 52364 DMVDYTG Systemic lupus erythematosus 4A40.0 Phase 1 [6]
CV8102 DMYD37G Melanoma 2C30 Phase 1 [7]
MEDI9197 DM0J7UR Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
SBT6050 DMHBD3T Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
VTX-1463 DM4ZIRK Allergic rhinitis CA08.0 Phase 1 [10]
DN1508052 DM0JT9C Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Toll-like receptor 8 (TLR8) TT8CWFK TLR8_HUMAN Inhibitor [1]

References

1 Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model. Eur J Immunol. 2016 Mar;46(3):772-81.
2 TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
3 Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5 Clinical pipeline report, company report or official report of Nektar Therapeutics.
6 Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
7 Clinical pipeline report, company report or official report of CureVac.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of Silverback Therapeutics.
10 VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
11 Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.